Products Affected - Description
Thyrolar oral tablet, Actavis (formerly Forest)
12.5 mcg/3.1 mcg 100 count (NDC 00456-0040-01)
25 mcg/6.25 mcg 100 count (NDC 00456-0045-01)
150 mcg/37.5 mcg 100 count (NDC 00456-0060-01)
100 mcg/25 mcg 100 count (NDC 00456-0055-01)
50 mcg/12.5 mcg 100 count (NDC 00456-0050-01)
Reason for the Shortage
Thyrolar tablets from Actavis (formerly Forest) are on shortage due to manufacturing changes.
No presentations are available.
Estimated Resupply Dates
Actavis (formerly Forest) has all Thyrolar presentations on long-term back order and the company cannot estimate a release date.
October 17, July 20, April 26, February 29, 2016; December 16, September 28, May 1, February 9, 2015; November 5, August 13, May 23, March 3, 2014; December 10, September 18, July 12, May 1, 2013; November 20, August 13, May 18, February 27, 2012; December 7, September 28, July 26, May 17, March 8, January 26, 2011; November 23, October 12, July 28, June 1, April 23, March 9, February 1, 2010; December 9, November 6, October 2, August 31, June 23 and 1, 2009; May 4, March 14, 2007; March 28, 2005, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins